The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
254 - I'm curious as to why the STI Innovicares program is allowed to advertise specific brand name drugs on a website without PAAB review; especially given two main pharmaceutical companies are behind a large promotion of their brands (AZ/Sanofi)? Isn't this considered DTC advertising linked to brand name drugs? The website is at www.innovicares.ca and also has DTC ads and posters in addition to the website.
Miscellaneous
1
Posts
1
Posters
390
Views
1
Watching
-
I have not reviewed the site as this is a forum for Q&A on the general meaning and application of the PAAB Code of Advertising Acceptance and not for advertising monitoring, reviews, or complaints. You may call me if you have questions about whether specific content on publicly accessible portions of the site exceed this restriction. As a general point, promotion of Rx drugs to consumers is permitted, but it is restricted to name, price, and quantity. You may call me if you have questions about whether specific content on publicly accessible portions of the site exceed this restriction. Note that Health Canada adjudicates complaints about DTC advertising of healthcare products.
